For the fourth quarter, we expect Xtemvi Net product sales to be in the range of $140 million to $145 million. While we continue to expect increases in weekly dispenses as compared to Q3, it is important to remember that fourth quarter demand is affected by several major conferences and holidays. Our Q4 guidance represents annual revenue of $440 million to $445 million an amazing accomplishment at this stage in the launch. We also expect inventory levels to be consistent with Q3 at about two and a half weeks, gross to net discounts to be in the range of 43 to 45%, driven by ongoing Medicare mixed dynamics. Looking beyond 2025, we expect the gross to net discount to stabilize in a similar range. We are also expecting Q4 operating expenses to be higher than Q3, reflecting variable costs tied to increased volumes in demand and an increase in our quarterly DTC investment, bringing our full-year DTC investment to the top end of our provided range of $70 to $80 million.

Nov 4, 2025 / CFO / receipt, needs a key / Jeff Farrow, CFO | earnings call 2025-11-04 | transcript 2b293695-d6d7-4114-bba9-7f902b04684e | chars 11692-12670 | segment 11